BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 26630576)

  • 1. High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients.
    Tan SH; Sapari NS; Miao H; Hartman M; Loh M; Chng WJ; Iau P; Buhari SA; Soong R; Lee SC
    PLoS One; 2015; 10(12):e0142466. PubMed ID: 26630576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
    Liedtke C; Cardone L; Tordai A; Yan K; Gomez HL; Figureoa LJ; Hubbard RE; Valero V; Souchon EA; Symmans WF; Hortobagyi GN; Bardelli A; Pusztai L
    Breast Cancer Res; 2008; 10(2):R27. PubMed ID: 18371219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
    Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
    J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer.
    Zhang Y; Liu M; Yang H; Wang J; Liu H; Li X; Li J; Xu J; Li X
    Neoplasma; 2014; 61(4):461-7. PubMed ID: 25027743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis.
    Ibrahim EM; Kazkaz GA; Al-Mansour MM; Al-Foheidi ME
    Breast Cancer Res Treat; 2015 Aug; 152(3):463-76. PubMed ID: 26105797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
    Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
    Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer.
    Yuan H; Chen J; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Clin Cancer Res; 2015 Oct; 21(19):4365-72. PubMed ID: 25979484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer.
    Lee J; Im YH; Lee SH; Cho EY; Choi YL; Ko YH; Kim JH; Nam SJ; Kim HJ; Ahn JS; Park YS; Lim HY; Han BK; Yang JH
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):569-77. PubMed ID: 17508214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
    McCarthy AM; Kumar NP; He W; Regan S; Welch M; Moy B; Iafrate AJ; Chan AT; Bardia A; Armstrong K
    BMC Cancer; 2020 Apr; 20(1):347. PubMed ID: 32326897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
    Guarneri V; Dieci MV; Frassoldati A; Maiorana A; Ficarra G; Bettelli S; Tagliafico E; Bicciato S; Generali DG; Cagossi K; Bisagni G; Sarti S; Musolino A; Ellis C; Crescenzo R; Conte P
    Oncologist; 2015 Sep; 20(9):1001-10. PubMed ID: 26245675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
    Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
    J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.
    Roy-Chowdhuri S; de Melo Gagliato D; Routbort MJ; Patel KP; Singh RR; Broaddus R; Lazar AJ; Sahin A; Alvarez RH; Moulder S; Wheler JJ; Janku F; Gonzalez-Angulo AM; Chavez-MacGregor M; Valero V; Ueno NT; Mills G; Mendelsohn J; Yao H; Aldape K; Luthra R; Meric-Bernstam F
    Am J Clin Pathol; 2015 Nov; 144(5):713-21. PubMed ID: 26486734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR
    Moynahan ME; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Ringeisen F; Hortobagyi GN; Baselga J; Chandarlapaty S
    Br J Cancer; 2017 Mar; 116(6):726-730. PubMed ID: 28183140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
    Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
    J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.
    Learn PA; Yeh IT; McNutt M; Chisholm GB; Pollock BH; Rousseau DL; Sharkey FE; Cruz AB; Kahlenberg MS
    Cancer; 2005 Jun; 103(11):2252-60. PubMed ID: 15834928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
    Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.